Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study

William E Moody, Benjamin Holloway, Parthiban Arumugam, Sharon Gill, Yasmin S Wahid, Chris M Boivin, Louise E Thomson, Daniel S Berman, Matthew J Armstrong, James Ferguson, Richard P Steeds, William E Moody, Benjamin Holloway, Parthiban Arumugam, Sharon Gill, Yasmin S Wahid, Chris M Boivin, Louise E Thomson, Daniel S Berman, Matthew J Armstrong, James Ferguson, Richard P Steeds

Abstract

Background: Although consensus-based guidelines support noninvasive stress testing prior to orthotopic liver transplantation (OLT), the optimal screening strategy for assessment of coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. This study sought to determine the relative predictive value of coronary risk factors, functional capacity, and single photon emission computed tomography (SPECT) on major adverse cardiovascular events and all-cause mortality in liver transplantation candidates.

Methods: Prior to listing for transplantation, 404 consecutive ESLD patients were referred to a University hospital for cardiovascular (CV) risk stratification. All subjects met at least one of the following criteria: inability to perform > 4 METs by history (62%), insulin-treated diabetes mellitus (53%), serum creatinine > 1.72 mg/dL (8%), history of MI, PCI or CABG (5%), stable angina (3%), cerebrovascular disease (1%), peripheral vascular disease (1%). Subjects underwent Technetium-99m SPECT with multislice coronary artery calcium scoring (CACS) using exercise treadmill or standard adenosine stress in those unable to achieve 85% maximal heart rate (Siemens Symbia T16). Abnormal perfusion was defined as a summed stress score (SSS) ≥ 4.

Results: Of the 404 patients, 158 (age 59 ± 9 years; male 68%) subsequently underwent transplantation and were included in the primary analysis. Of those, 50 (32%) died after a mean duration follow-up of 5.4 years (maximal 10.9 years). Most deaths (78%) were attributed to noncardiovascular causes (malignancy, sepsis, renal failure). Of the 32 subjects with abnormal perfusion (20%), nine (6%) had a high-risk perfusion abnormality defined as a total perfusion defect size (PDS) ≥ 15% and/or an ischemic PDS ≥ 10%. Kaplan-Meier survival curves demonstrated abnormal perfusion was associated with increased CV mortality (generalized Wilcoxon, P = 0.014) but not all-cause death. Subjects with both abnormal perfusion and an inability to exercise > 4 METs had the lowest survival from all-cause death (P = 0.038). Abnormal perfusion was a strong independent predictor of CV death (adjusted HR 4.2; 95% CI 1.4 to 12.3; P = 0.019) and MACE (adjusted HR 7.7; 95% CI 1.4 to 42.4; P = 0.018) in a multivariate Cox regression model that included age, sex, diabetes, smoking and the ability to exercise > 4 METs. There was no association between CACS and the extent of perfusion abnormality, nor with outcomes.

Conclusions: Most deaths following OLT are noncardiovascular. Nonetheless, abnormal perfusion is prevalent in this high-risk population and a stronger predictor of cardiovascular morbidity and mortality than functional status. A combined assessment of functional status and myocardial perfusion identifies those at highest risk of all-cause death. (Exercise Capacity and Single Photon Emission Computed Tomography in Liver Transplantation Candidates [ExSPECT]; ClinicalTrials.gov Identifier: NCT03864497).

Keywords: SPECT; diagnostic and prognostic application; exercise testing; outcomes research; vasodilators.

© 2020. The Author(s).

Figures

Figure 1
Figure 1
Study consort diagram. Abbreviations: OLT, orthotopic liver transplantation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery
Figure 2
Figure 2
Relation between CACS severity and stress SPECT results (n = 84). The percentage of subjects with a normal SPECT result was highest in those with minimal CACS (P < 0.001). A 4 × 2 contingency analysis was performed using a two-tailed Fisher’s exact test to determine significance
Figure 3
Figure 3
Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death and (B) all-cause death according to perfusion dichotomized by a summed stress score ≥ 4. Two-sided generalized Wilcoxon tests were used to determine significance
Figure 4
Figure 4
Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death and (B) all-cause death according to functional capacity dichotomized by estimated METs ≤ 4. Two-sided generalized Wilcoxon tests were used to determine significance
Figure 5
Figure 5
Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death and (B) all-cause death according to integrated results of SPECT and exercise capacity. Two-sided generalized Wilcoxon tests were used to determine significance
Figure 6
Figure 6
Annualized event rates for (A) cardiovascular death and (B) all-cause death according to integrated results of SPECT and exercise capacity. (A) For each subgroup (number of CV deaths/number of patients): METs ≥ 4, normal perfusion (1/59); METs <4, normal perfusion (4/67); METs ≥ 4, abnormal perfusion (2/15); METS <4, abnormal perfusion (4/17). (B) For each subgroup (number of all-cause deaths / number of patients): METs ≥ 4, normal perfusion (15/60); METs <4, normal perfusion (26/66); METs ≥ 4, abnormal perfusion (2/15); METS <4, abnormal perfusion (7/17)
Figure 7
Figure 7
Incremental predictive value of exercise capacity and stress SPECT results over clinical information to predict cardiovascular death. The clinical data entered into the global Chi-square analysis model included age, sex, diabetes, smoking history. Abnormality on SPECT (defined as SSS ≥ 4) and exercise capacity (METs
All figures (7)

References

    1. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA. Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60:434–480.
    1. Snipelisky D, Levy M, Shapiro B. Utility of dobutamine stress echocardiography as part of the pre-liver transplant evaluation: An evaluation of its efficacy. Clin Cardiol. 2014;37:468–472.
    1. Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, Flamm SL, Blei AT, Bonow RO, Abecassis M, Gheorghiade M. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transpl. 2008;8:1523–1528.
    1. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation. 2000;69:2354–2356.
    1. Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transpl. 2008;14:886–892.
    1. Davidson CJ, Gheorghiade M, Flaherty JD, Elliot MD, Reddy SP, Wang NC, Sundaram SA, Flamm SL, Blei AT, Abecassis MI, Bonow RO. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol. 2002;89:359–360.
    1. Bhutani S, Tobis J, Gevorgyan R, Sinha A, Suh W, Honda HM, Vorobiof G, Packard RR, Steadman R, Wray C, Busuttil R, Tseng CH. Accuracy of stress myocardial perfusion imaging to diagnose coronary artery disease in end stage liver disease patients. Am J Cardiol. 2013;111:1057–1061.
    1. Abele JT, Raubenheimer M, Bain VG, Wandzilak G, AlHulaimi N, Coulden R, deKemp RA, Klein R, Williams RG, Warshawski RS, Lalonde LD. Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using (82)Rb PET/CT. J Nucl Cardiol. 2018;1:1. doi: 10.1007/s12350-018-01516-8.
    1. Martin P, DiMartini A, Feng S, Brown R, Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–1165.
    1. VanWagner LB, Harinstein ME, Runo JR, Darling C, Serper M, Hall S, Kobashigawa JA, Hammel LL. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. Am J Transpl. 2018;18:30–42.
    1. Snipelisky D, Ray J, Vallabhajosyula S, Matcha G, Squier S, Lewis J, Holliday R, Aggarwal N, Askew JW, 3rd, Shapiro B, Anavekar N. Usefulness for predicting cardiac events after orthotopic liver transplantation of myocardial perfusion imaging and dobutamine stress echocardiography preoperatively. Am J Cardiol. 2017;119:1008–1011.
    1. Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Rosenbaum L, Shaw LJ, Stainback RF, Allen JM, American College of Cardiology Foundation Appropriate Use Criteria Task F ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2013;2014(63):380–406.
    1. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, Flamm S, Davidson CJ, Gheorghiade M. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178–181.
    1. Safadi A, Homsi M, Maskoun W, Lane KA, Singh I, Sawada SG, Mahenthiran J. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation. 2009;120:1189–1194.
    1. Guckelberger O, Thelen A, Benckert C, Schoebel C, Reuter S, Klupp J, Jonas S, Neuhaus P. Diabetes mellitus is no independent risk factor for perioperative mortality following hepatic resection. Exp Clin Endocrinol Diabetes. 2006;114:257–261.
    1. Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, Neuhaus P, Langrehr JM. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl. 2006;12:394–401.
    1. Appleton CP, Hurst RT. Reducing coronary artery disease events in liver transplant patients: Moving toward identifying the vulnerable patient. Liver Transpl. 2008;14:1691–1693.
    1. Hogan BJ, Gonsalkorala E, Heneghan MA. Evaluation of coronary artery disease in potential liver transplant recipients. Liver Transpl. 2017;23:386–395.
    1. Prentis JM, Manas DM, Trenell MI, Hudson M, Jones DJ, Snowden CP. Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. Liver Transpl. 2012;18:152–159.
    1. Epstein SK, Freeman RB, Khayat A, Unterborn JN, Pratt DS, Kaplan MM. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl. 2004;10:418–424.
    1. Baker S, Chambers C, McQuillan P, Janicki P, Kadry Z, Bowen D, Bezinover D. Myocardial perfusion imaging is an effective screening test for coronary artery disease in liver transplant candidates. Clin Transpl. 2015;29:319–326.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Epidemiology. 2007;18:800–804.
    1. Karamitsos TD, Ntusi NA, Francis JM, Holloway CJ, Myerson SG, Neubauer S. Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:66.
    1. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, Ficaro EP, Freeman MR, Hendel RC, Jain D, Leonard SM, Nichols KJ, Polk DM, Soman P. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941–973.
    1. Berman DS, Kiat H, Friedman JD, Wang FP, van Train K, Matzer L, Maddahi J, Germano G. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: A clinical validation study. J Am Coll Cardiol. 1993;22:1455–1464.
    1. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535–543.
    1. Chang SM, Nabi F, Xu J, Peterson LE, Achari A, Pratt CM, Mahmarian JJ. The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk. J Am Coll Cardiol. 2009;54:1872–1882.
    1. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832.
    1. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74:243–252.
    1. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res. 1971;3:323–332.
    1. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O’Reilly MG, Winters WL, Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Jr, American College of Cardiology/American Heart Association Task Force on Practice G ACC/AHA 2002 guideline update for exercise testing: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) Circulation. 2002;2002(106):1883–1892.
    1. Jette M, Sidney K, Blumchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol. 1990;13:555–565.
    1. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J. 1973;85:546–562.
    1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969.
    1. Shah R, Gleadle JM, Selvanayagam JB. Predicting cardiac prognosis in asymptomatic chronic kidney disease patients. JACC Cardiovasc Imaging. 2018;11:286–287.
    1. National Health Service HSCIC. Hospital Episodes Statistics Online Database 2019. . Accessed 1 Aug 2019.
    1. National Health Service. OPCS-4 Classification e NHS connecting for health 2019. . Accessed 1 Aug 2019.
    1. World Health Organisation. International classification of diseases (ICD) 2019. . Accessed 1 Aug 2019.
    1. Kong YG, Kang JW, Kim YK, Seo H, Lim TH, Hwang S, Hwang GS, Lee SG. Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients. Br J Anaesth. 2015;114:437–443.
    1. Organ Procurement and Transplantation Network. Health Resources and Services Administration. US Department of Health. 2019. . Accessed 1 Aug 2019.
    1. Zoghbi GJ, Patel AD, Ershadi RE, Heo J, Bynon JS, Iskandrian AE. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol. 2003;92:1066–1071.
    1. Appleton CP, Hurst RT, Lee KS, Reuss C, Hentz JG. Long-term cardiovascular risk in the orthotopic liver transplant population. Liver Transpl. 2006;12:352–355.
    1. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE, Investigators D. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial. JAMA. 2009;301:1547–1555.
    1. Goraya TY, Jacobsen SJ, Pellikka PA, Miller TD, Khan A, Weston SA, Gersh BJ, Roger VL. Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med. 2000;132:862–870.
    1. Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989;262:2395–2401.
    1. Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, Al-Hani AJ, Black HR. Exercise capacity and the risk of death in women: The St James Women Take Heart Project. Circulation. 2003;108:1554–1559.
    1. Kokkinos P, Myers J, Kokkinos JP, Pittaras A, Narayan P, Manolis A, Karasik P, Greenberg M, Papademetriou V, Singh S. Exercise capacity and mortality in black and white men. Circulation. 2008;117:614–622.
    1. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1:e183605.
    1. Bradley SM, Soine LA, Caldwell JH, Goldberg SL. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. Am J Cardiol. 2010;105:1010–1013.
    1. Kemmer N, Case J, Chandna S, Neff GW. The role of coronary calcium score in the risk assessment of liver transplant candidates. Transpl Proc. 2014;46:230–233.
    1. Akincioglu C, Malhotra S. Low yield of routine stress testing in patients awaiting liver transplantation. J Nucl Cardiol. 2020;27:266–268.
    1. Poulin MF, Chan EY, Doukky R. Coronary computed tomographic angiography in the evaluation of liver transplant candidates. Angiology. 2015;66:803–810.
    1. Satapathy SK, Vanatta JM, Helmick RA, Flowers A, Kedia SK, Jiang Y, Ali B, Eason J, Nair SP, Ibebuogu UN. Outcome of liver transplant recipients with revascularized coronary artery disease: A comparative analysis with and without cardiovascular risk factors. Transplantation. 2017;101:793–803.
    1. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351:2795–2804.
    1. Wong EY, Lawrence HP, Wong DT. The effects of prophylactic coronary revascularization or medical management on patient outcomes after noncardiac surgery—A meta-analysis. Can J Anaesth. 2007;54:705–717.

Source: PubMed

3
Abonnere